Gossamer Bio/$GOSS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Ticker
$GOSS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
145
ISIN
US38341P1021
Website
Gossamer Bio Metrics
BasicAdvanced
$286M
-
-$0.23
1.82
-
Price and volume
Market cap
$286M
Beta
1.82
52-week high
$1.55
52-week low
$0.50
Average daily volume
1.6M
Financial strength
Current ratio
5.713
Quick ratio
5.485
Long term debt to equity
-3,230.944
Total debt to equity
-3,244.592
Interest coverage (TTM)
-4.92%
Management effectiveness
Return on assets (TTM)
-12.68%
Return on equity (TTM)
-500.57%
Valuation
Price to revenue (TTM)
2.291
Price to book
-45.81
Price to tangible book (TTM)
-45.81
Price to free cash flow (TTM)
31.417
Growth
Earnings per share change (TTM)
-75.71%
3-year earnings per share growth (CAGR)
-58.26%
What the Analysts think about Gossamer Bio
Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.
Gossamer Bio Financial Performance
Revenues and expenses
Gossamer Bio Earnings Performance
Company profitability
Gossamer Bio News
AllArticlesVideos
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gossamer Bio stock?
Gossamer Bio (GOSS) has a market cap of $286M as of June 06, 2025.
What is the P/E ratio for Gossamer Bio stock?
The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of June 06, 2025.
Does Gossamer Bio stock pay dividends?
No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Gossamer Bio dividend payment date?
Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.
What is the beta indicator for Gossamer Bio?
Gossamer Bio (GOSS) has a beta rating of 1.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.